Drug Trial Radar · NCT07227285
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Apr 2031
Study completion Apr 2031
Sponsor
- Lead sponsor
- Cyllene TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.
Conditions
- Urinary Bladder, Overactive
- Spinal Cord Injury
Interventions
UrodynamicsOther
standardized local evaluation of urodynamic parameters
EG110ADrug
Patients already treated with EG110A
Patient-reported OutcomeOther
assessment of participant's perception of the level of impairment in functioning and well-being associated with NDO symptoms
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent serious adverse events (TESAEs)Time frame: 5 years
- Incidence of treatment emergent adverse events (TEAEs) including treatment emergent averse events of special interest (TEAESIs)Time frame: 5 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Rancho Los Amigos National Rehabilitation Center
Downey, California
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Sidney Kimmel Medical College
Philadelphia, Pennsylvania
UTHealth Houston / TIRR Memorial Hermann
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.